Pancreatic Cancer Research

ResearcherTongji UniversityActive in the last 2 years

Jian Hua Sun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4997-2604; OpenAlex author ID A5100687624. Sources: OpenAlex.

Their work

Papers
12 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
36
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 6 papers · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 12

  1. MSI2 regulates NLK-mediated EMT and PI3K/AKT/mTOR pathway to promote pancreatic cancer progression. First author DOI 10.1186/s12935-024-03444-9↗
  2. ATP11A promotes EMT by regulating Numb PRR L in pancreatic cancer cells. Co-author DOI 10.7717/peerj.13172↗
  3. Genetic aberrations in Chinese pancreatic cancer patients and their association with anatomic location and disease outcomes. Co-author DOI 10.1002/cam4.3679↗
  4. MiR-338-5p Inhibits EGF-Induced EMT in Pancreatic Cancer Cells by Targeting EGFR/ERK Signaling. Co-author DOI 10.3389/fonc.2021.616481↗
  5. Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study. Co-author DOI 10.1016/j.ebiom.2020.102767↗
  6. Integrated analysis identifies a pathway-related competing endogenous RNA network in the progression of pancreatic cancer. Co-author DOI 10.1186/s12885-020-07470-4↗
  7. Correction to: Musashi2 promotes EGF-induced EMT in pancreatic cancer via ZEB1-ERK/MAPK signaling. Co-author DOI 10.1186/s13046-020-01663-2↗
  8. Calreticulin promotes EMT in pancreatic cancer via mediating Ca2+ dependent acute and chronic endoplasmic reticulum stress. Co-author DOI 10.1186/s13046-020-01702-y↗
  9. Musashi2 promotes EGF-induced EMT in pancreatic cancer via ZEB1-ERK/MAPK signaling. Co-author DOI 10.1186/s13046-020-1521-4↗
  10. The Lipid Metabolites Profile in Patients with Pancreatic Cancer: A Controlled Study of Cancer Tissue Versus Matched Para-Cancer Tissue First author DOI 10.21203/rs.3.rs-127782/v1↗
  11. PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay. First author DOI 10.1186/s13000-017-0678-4↗
  12. WT1-associated protein is a novel prognostic factor in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2017.5784↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ming Dong · 6 shared papers, 2020–2024 · strength 0.99
  2. Weiwei Sheng · 5 shared papers, 2020–2022 · strength 0.63
  3. Rongxian Cao · 3 shared papers, 2020 · strength 0.32
  4. Guosen Wang · 3 shared papers, 2020 · strength 0.32
  5. Chao Jia · 3 shared papers, 2020 · strength 0.32
  6. Zhiyong Liang · 3 shared papers, 2018–2021 · strength 0.29
  7. Longping Huang · 1 shared paper, 2024 · strength 0.26
  8. Junchao Guo · 3 shared papers, 2017–2020 · strength 0.24
  9. Xiaolong Liang · 2 shared papers, 2018–2021 · strength 0.20
  10. Huanwen Wu · 2 shared papers, 2018–2021 · strength 0.20
  11. Zhiwen Zhang · 2 shared papers, 2018–2021 · strength 0.20
  12. Junliang Lu · 2 shared papers, 2018–2021 · strength 0.20
  13. Lin Chen · 1 shared paper, 2022 · strength 0.19
  14. Li Zhou · 2 shared papers, 2017–2020 · strength 0.16
  15. Quan Liao · 2 shared papers, 2017–2020 · strength 0.16
  16. Taiping Zhang · 2 shared papers, 2017–2020 · strength 0.16
  17. Lei You · 2 shared papers, 2017–2020 · strength 0.16
  18. Peng Liu · 1 shared paper, 2020 · strength 0.13
  19. Fuqiang Zu · 1 shared paper, 2020 · strength 0.13
  20. Xiaodong Tan · 1 shared paper, 2020 · strength 0.13
  21. Hui Zhang · 1 shared paper, 2021 · strength 0.12
  22. Rui Liu · 1 shared paper, 2021 · strength 0.12
  23. Jianping Zhou · 1 shared paper, 2020 · strength 0.11
  24. Xin Yu Wang · 1 shared paper, 2020 · strength 0.10
  25. Xu Hong · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.